Strategies of immunosuppression for liver transplant recipients with hepatocellular carcinoma

Transplantation Proceedings

Volumn 43, Issue 3, 2011, Pages 711-713

  Castroagudin J F ^a   Molina Prez, E ^a   Ferreiro Iglesias, R ^a   Varo Prez, E ^a  

^a Pediatric Nutrition Research Group Health Research Institute of Santiago de Compostela   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN A; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; RAPAMYCIN; TACROLIMUS;

ANTINEOPLASTIC ACTIVITY; CANCER RECURRENCE; CANCER STAGING; CLINICAL PROTOCOL; CONFERENCE PAPER; DRUG EFFICACY; DRUG SAFETY; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; OVERALL SURVIVAL; PATIENT SELECTION; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL RATE; TUMOR GROWTH;

CARCINOMA, HEPATOCELLULAR; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER CIRRHOSIS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; NEOPLASM RECURRENCE, LOCAL;

EID: 79954456370     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2011.01.090     Document Type: Conference Paper

References (25)

1. J. Bruix, M. Sherman Practice Guidelines Committee, American Association for the Study of Liver Diseases Management of hepatocellular carcinoma Hepatology 42 2005 1208
2. V. Mazzaferro, E. Regalia, and R. Doci Liver transplantation for treatment of small hepatocellular carcinomas in patients with cirrhosis N Engl J Med 334 1996 693
3. J.F. Castroagudin, E. Molina, and M. Bustamante Orthotopic liver transplantation for hepatocellular carcinoma: a thirteen-year single-center experience Transplant Proc 40 2008 2975
4. I. Penn The problem of cancer in organ transplant recipients Transplant Sci 4 1994 23
5. D.M. Kelly, S. Emre, and S.R. Guy Liver transplant recipients are not at increased risk for nonlymphoid solid organ tumors Cancer 83 1998 1237
6. M.L. Kripe Immnunoregulation of carcinogenesis: past, present and future J Natl Cancer Inst 80 1998 722
7. P. Majno, E. Giostra, G. Mentha Geneva Liver Cancer Study Group Is there a customised immunosuppressive regimen for patients transplanted with hepatocellular carcinoma? J Hepatol 43 2005 577
8. M. Guba, C. Graeb, and K.W. Jauch Pro- and anticancer effects of immunosupressive agents used in liver transplantation Transplantation 77 2004 1777
9. M. Herman, T. Weinstein, and A. Korzets Effect of cyclosporine A on DNA repair and cancer incidence in kidney transplant recipients J Lab Clin Med 137 2001 14
10. C.E. Freise, L. Ferrell, and T. Liu Effect of systemic cyclosporine on tumor recurrence after liver transplantation in a model of hepatocellular carcinoma Transplantation 67 1999 510
11. I. Yokoyama, B. Carr, and H. Saitsu Accelerated growth rates of recurrent hepatocellular carcinoma after liver transplantation Cancer 68 1991 2095
12. R. Steininger, F. Herbst, and R. Fgger Immunosupression does not enhance tumor growth after orthotopic liver transplantation for hepatoma Transplant Proc 24 1992 2690
13. M. Vivarelli, R. Bellusci, and A. Cucchetti Low recurrence rate of hepatocellular carcinoma after liver transplantation: better patient selection or lower immunosuppression? Transplantation 74 2002 1746
14. M. Vivarelli, A. Cucchetti, and F. Piscaglia Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosupression Liver Transpl 11 2005 497
15. N. Guba, P. von Breintenbuch, and M. Steinbauer Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor Nat Med 8 2002 128
16. J.M. Campistol, J. Eris, and R. Oberbauer Sirolimus therapy after early cyclosporine withdrawal reduces the risk of cancer in adult renal transplantation J Am Soc Nephrol 17 2006 581
17. H.M. Kauffman, W.S. Cherikh, and Y. Cheng Maintenance immunosupression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies Transplantation 80 2005 883
18. N.M. Kneteman, J. Oberholzer, and M. Al Saghier Sirolimus- immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma Liver Transpl 10 2004 1301
19. M.A. Zimmerman, J.F. Trotter, and M. Wachs Sirolimus-based immunosupression following liver transplantation for hepatocellular carcinoma Liver Transpl 14 2008 633
20. J. Zhou, Z. Wang, and Q. Wu Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria Transplant Proc 40 2008 3548
21. M. Vivarelli, A. Dazzi, and M. Zanello Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma Transplantation 89 2010 227
22. C. Toso, S. Merani, and D.L. Bigam Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma Hepatology 51 2010 1237
23. A. Nocera, E. Andorno, and A. Tagliamacco Sirolimus therapy in liver transplant patients: an initial experience at a single center Transplant Proc 40 2008 1950
24. J.F. Castroagudin, E. Molina, and S. Tom Safety of an immunosuppressant protocol based on sirolimus in liver transplant recipients with malignancies or high risk of tumor recurrence Transplant Proc 41 2009 1003
25. C. Toso, G.A. Meeberg, and D.L. Bigam De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects Transplantation 83 2007 1162